FRTD Fortitude Group Inc (CE)

Erie, PA., January 28, 2013 – Fortitude Group Inc., Today introduces Anthony J. Colantonio, MD Chief Medical Innovation Officer of the Life Science Division.

Fortitude Group Inc., (Ticker Symbol FRTD) CEO Thomas Parilla is pleased to announce Anthony J. Colantonio, MD accepted the position of Chief Medical Innovation Officer of the Life Science Division.

Dr. Colantonio completed fellowship training in Interventional Pain Medicine at the Oregon Health and Science University, residency training at Duke University in Anesthesiology, and medical and undergraduate education at Georgetown University and is a Diplomat of the American Board of Anesthesiology and the American Academy of Pain Management.  Dr. Colantonio is the Director of the Clinic for Specialty Pain Services at Meadville Medical Center, with a clinical focus upon neuromodulation therapy and geriatric care.  Dr. Colantonio is a regional key opinion leader for numerous pharmaceutical and medical device companies and a national speaker for Pfizer Pharmaceuticals. 

As a clinician-inventor, Colantonio is a tireless advocate for patients and medical providers and has dedicated his entrepreneurial career to identifying critical healthcare problems and solving them with innovative products and services.  Anthony holds two utility patents through the USPTO and six patents pending.  As the Chief Medical Officer of the Life Science Division, Dr. Colantonio leads the research and development efforts from initial product design to bench-top testing, clinical trials, and final product validation through the company’s regulatory and quality efforts.  Dr. Colantonio plays a critical role in the development of professional partnerships with leading healthcare institutions, and key opinion leaders in the fields of anesthesia, interventional pain management, and infection prevention services with specific emphasis upon the reduction of healthcare acquired conditions (HACs).  "There is a very bright future ahead. We are in a unique position to have a significant impact upon improving outcomes for patients by tackling healthcare acquired complications head on, and from multiple solution angles. Exciting and revolutionary changes have been waiting to happen in healthcare, and Fortitude is bringing that wait to an end."  Dr. Colantonio stated.

"Anthony’s clinical expertise and entrepreneurial vision is a vital asset to the creation of our life science division".   Mr. Parilla stated.

Mr. Parilla added, “As we build our life science division, shareholders will soon recognize the unique opportunity that has been created. The strategic plan now being deployed will aggressively move the Fortitude Group Inc. into a strong position within the life science medical device market. Dr. Colantonio will be working closely with the head of the life science division Chris Cuzzola.  The Fortitude Group will be providing more in-depth news on the growth of this Division in the very near future.”

About:

Fortitude Group Inc. develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures.  The Company’s service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated healthcare acquired conditions and improve clinical outcomes.

Safe Harbor:

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly revise any forward-looking statements.

Contact

Sterling Capitol Investor Relations

Kent Thomas

Phone – (631) 824-7661

Email – IR-FRTD@sterlingcapitol.net

Fortitude (CE) (USOTC:FRTD)
Historical Stock Chart
From Dec 2024 to Jan 2025

Fortitude (CE) (USOTC:FRTD)
Historical Stock Chart
From Jan 2024 to Jan 2025